Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

University of British Columbia

$17,500.00

FY 2019-20

Summary
"Prostate cancer (PCa) is the second-leading cause of cancer-related deaths in men, where inhibition of androgen receptor (AR) is the standard-of-care to treat recurrent or metastatic PCa. While this is initially effective, resistance often develops, resulting in a more aggressive castration-resistant prostate cancer (CRPC). One resistance mechanism is expression of constitutively active androgen receptor splice variants, most commonly AR-V7. Recent work demonstrated that the binding sites of AR-V7 are largely the same as the flAR while the transcriptional activity is very different, suggesting they may recruit different co-regulatory proteins in a locus-dependent manner. The goal of the proposed project is to identify these different co-regulatory proteins to better understand AR-V7's mechanism of action. To characterize the AR-V7 interactome we developed a novel protein ligation assay, generating a ""split"" version of a protein that is only active when the two fragments are held in close proximity. By fusing these fragments to AR or AR-V7 the split proteins will be activated only when dimerization of the AR proteins occurs and the two fragments are complemented. Once this occurs they will regain its function and begin biotinylating proteins in the immediate vicinity of the AR dimers. This, combined with streptavidin pulldown and mass spectrometry, will allow global identification of AR and AR-V7's interaction partners, which may play an important but as yet unrecognized role in CRPC. Once identified, we will validate and characterize ""hit"" interacting proteins. Through this novel approach, this work will allow us to glean further insight into both AR and AR-V7 signalling and help to improve treatment of CRPC patients."
Program
Master's Award: Canada Graduate Scholarships
Location
British Columbia, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
429133
Name
Yu Ivan P
Region
British Columbia
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Unknown
Programtype2
Studentship Programs
Orgnameinp2
University of British Columbia
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Androgen Receptor; Androgen Receptor Variant 7; Biotin-Labelling; Co-Factors; In-Vitro; Interactomes; Mass Spectrometry; Prostate Cancer; Split-Proteins
Abstract
"Prostate cancer (PCa) is the second-leading cause of cancer-related deaths in men, where inhibition of androgen receptor (AR) is the standard-of-care to treat recurrent or metastatic PCa. While this is initially effective, resistance often develops, resulting in a more aggressive castration-resistant prostate cancer (CRPC). One resistance mechanism is expression of constitutively active androgen receptor splice variants, most commonly AR-V7. Recent work demonstrated that the binding sites of AR-V7 are largely the same as the flAR while the transcriptional activity is very different, suggesting they may recruit different co-regulatory proteins in a locus-dependent manner. The goal of the proposed project is to identify these different co-regulatory proteins to better understand AR-V7's mechanism of action. To characterize the AR-V7 interactome we developed a novel protein ligation assay, generating a ""split"" version of a protein that is only active when the two fragments are held in close proximity. By fusing these fragments to AR or AR-V7 the split proteins will be activated only when dimerization of the AR proteins occurs and the two fragments are complemented. Once this occurs they will regain its function and begin biotinylating proteins in the immediate vicinity of the AR dimers. This, combined with streptavidin pulldown and mass spectrometry, will allow global identification of AR and AR-V7's interaction partners, which may play an important but as yet unrecognized role in CRPC. Once identified, we will validate and characterize ""hit"" interacting proteins. Through this novel approach, this work will allow us to glean further insight into both AR and AR-V7 signalling and help to improve treatment of CRPC patients."
Competitiondate
201912
Approvedterm2
1 yr 0 mth
Pinamesdelim
Yu, Ivan P
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~